- 321 Downloads
Tianeptine is an antidepressant agent with a novel neurochemical profile. It increases serotonin (5-hydroxytryptamine; 5-HT) uptake in the brain (in contrast with most antidepressant agents) and reduces stress-induced atrophy of neuronal dendrites. Like the selective serotonin reuptake inhibitors (SSRIs) and in contrast with most tricyclic antidepressant agents, tianeptine does not appear to be associated with adverse cognitive, psychomotor, sleep, cardiovascular or bodyweight effects and has a low propensity for abuse.
Tianeptine has a comparatively favourable pharmacokinetic profile. It is not subject to first-pass hepatic metabolism, has high bioavailability and limited distribution, and is rapidly eliminated. While this offers advantages for tianeptine over the tricyclic antidepressant agents in terms of dose titration, treatment changes and potential drug interactions, its rapid elimination makes adherence to dosage schedules more important. Tianeptine differs from most antidepressants in that it is not primarily metabolised by the hepatic cytochrome P450 system, indicating less likelihood of drug-drug interactions; this is of particular interest for elderly patients.
Tianeptine, in dosages of 25 to 50 mg/day, has been investigated in patients with major depression, depressed bipolar disorder, dysthymia or adjustment disorder. It has equivalent antidepressant efficacy to several classical antidepressant agents (amitriptyline, clomipramine, imipramine, mianserin) and the SSRIs fluoxetine (in most patients), paroxetine and sertraline. Comparison with maprotiline indicated superior efficacy for tianeptine but dothiepin appeared superior in another study. Extended treatment with tianeptine decreases the incidence of relapse/ recurrence of depression.
Tianeptine appears to be as effective as fluoxetine, sertraline, amitriptyline, clomipramine and mianserin and more effective than maprotiline in improving associated anxiety in patients with depressive disorders. Depression and anxiety symptoms in alcohol dependant patients also respond well to tianeptine.
The adverse effects associated with tianeptine are similar in many respects to those of the SSRIs and minimal in comparison with the tricyclic antidepressants. The most common adverse effects are nausea, constipation, abdominal pain, headache, dizziness and changes in dreaming. Anticholinergic effects occur less often with tianeptine than with tricyclic agents. Hepatoxicity is rare. The dosage should be decreased in elderly patients and those with severe renal failure, but adjustment is not necessary in patients with alcoholism or hepatic impairment, or those undergoing haemodialysis.
Conclusions: The antidepressant efficacy and favourable tolerability and pharmacokinetic profiles of tianeptine in patients with depression, including those with associated anxiety, have been proven; the data indicate that it may have additional potential in specific subgroups of depressed patients such as the elderly and those with chronic alcoholism.
Tianeptine is an antidepressant drug with structural similarities to the tricyclic antidepressant agents but a novel neurochemical profile. The main difference between this and other antidepressant agents is its action on serotonin (5-hydroxytryptamine; 5-HT): tianeptine increases serotonin uptake in the brain and platelets. The behavioural (in animal models) and physical (atrophy of neuronal dendrites) effects of stress on the hypothalamic-pituitary-adrenal axis are reduced by tianeptine, and levels of noradrenaline (norepinephrine) and dopamine are indirectly increased in several regions of the brain. The main metabolite (MC5; pentanoic acid) has some minor antidepressant activity.
Clinical studies indicate that, unlike tricyclic antidepressant agents, tianeptine is not associated with adverse effects on driving skills or cognitive function (such as sedation or impaired memory) and may have slight activating properties, particularly in aspects of attention. Similarly, there appear to be few effects on sleep in healthy volunteers or patients with concurrent depression and alcoholism after withdrawal of alcohol.
Like the selective serotonin reuptake inhibitors (SSRIs) and in contrast with the tricyclic antidepressants, tianeptine has a favourable cardiovascular profile in healthy volunteers and patients with depression, with and without concurrent alcoholism.
The maximum plasma concentration (Cmax) of tianeptine was 0.3 mg/L, time to Cmax (tmax) was 0.94 hours and bioavailability was 99% after a single oral dose of tianeptine 12.5mg in healthy volunteers. The drug is not subject to first-pass hepatic metabolism. Food decreases Cmax and prolongs tmax but does not affect the extent of absorption. Although the distribution of tianeptine is rapid (distribution half-life 0.7 hours) protein binding is high (95%), resulting in alow volume of distribution (0.5 to 0.8 L/kg) in healthy volunteers.
Tianeptine undergoes extensive extrarenal metabolism and has a short elimination half-life (t1/2β; 2.5 hours in healthy volunteers). The major metabolic pathway of tianeptine is a 2-step β-oxidation process of the aliphatic chain, leading to the formation of 2 main metabolites MC5 and MC3 (propionic acid). MC3 is the main metabolite of tianeptine in urine and MC5 is the main metabolite in plasma. Tianeptine does not undergo cytochrome P450—dependent biotransformation to any significant extent, thus reducing the risk of drug interactions.
The pharmacokinetic profile of a single dose of tianeptine in adults with depression appears similar to that in healthy adult volunteers, although the tmax and t12β were prolonged. Steady-state pharmacokinetics were achieved after 1 month of treatment with tianeptine 37.5 mg/day and were maintained over 3 months. Most values were similar to those seen in depressed patients after a single dose, but the area under the concentration-time curve (AUC) was significantly greater after extended treatment (1.3 vs 1 mg/L · h; p < 0.03).
The pharmacokinetic profile of oral tianeptine was not significantly altered in patients with compromised renal function. However, the t1/2β and AUC of the MC5 metabolite were increased compared with controls, suggesting a decreased clearance of this metabolite in patients with renal failure. Although bioavailability of tianeptine remained high (85%) in elderly individuals, clearance was lower than that reported in younger individuals. The pharmacokinetic profile of tianeptine is not altered in patients with alcoholic cirrhosis and depression.
The clinical antidepressant efficacy of tianeptine 25 to 50 mg/day has been proven against placebo in patients aged 18 to 60 years with major depression (single episode or recurrent) or bipolar disorder (depressed) in 2 double-blind trials. Initial improvements were seen after 7 days, and improvement continued throughout the 6 weeks of study. Improvements from baseline on the Montgomery-Åsberg Depression Rating Scale (MÅDRS) were 44 and 54% with tianeptine and 28 and 38% in placebo recipients (p < 0.05 and p < 0.01, respectively).
Tianeptine 25 to 37.5 mg/day for 1.5 to 3 months had equivalent antidepressant efficacy to fluoxetine 20 mg/day in patients with major depression (single episode or recurrent), bipolar disorder (depressed) or dysthymic disorder in several studies. However, although equivalence was noted in several parameters in elderly patients receiving tianeptine or fluoxetine in one study, reductions from baseline in the MÅDRS scores were statistically significantly greater in those receiving fluoxetine (62 vs 51% in fluoxetine and tianeptine recipients, respectively, compared with 50 vs 51%, respectively, in a study in patients aged 18 to 65 years which used this assessment tool). The antidepressant efficacy of tianeptine 37.5 mg/day (reduction in MÅDRS score of 56%) was equivalent to that of sertraline 50 mg/day (reduction of 54%) after 1.5 months in patients with major depression or bipolar disorder. A study published only in abstract form indicates that tianeptine 37.5 mg/day has similar efficacy to paroxetine 20 mg/day for 3 months (reductions in MÅDRS scores of 62 and 61%, respectively).
In comparative studies with tricyclic or tetracyclic antidepressant agents, the antidepressant efficacy of tianeptine 25 to 50 mg/day (44 to 64% reduction in MÅDRS scores) was equivalent to that of amitriptyline 50 to 100 mg/day for 1 or 1.5 months (53 and 69%), clomipramine 100 to 200 mg/day for 6 months (55%), imipramine 100 to 200 mg/day for 1.5 months (41%) and mianserin 30 to 80 mg/day for 1.5 or 6 months (48 and 50%) in patients with major depression (single episode or recurrent), bipolar disorder (depressed), dysthymic disorder or adjustment disorder. Tianeptine 37.5 mg/day (56% reduction in MÅDRS score) was more effective than maprotiline 75 mg/day for 2 months (47%) in a study of perimenopausal women with anxio-depressive symptoms and less effective than dothiepin 150 to 225 mg/day for 1 month in a small study of patients with depressive disorders.
The anxiolytic efficacy of tianeptine was assessed in several comparative trials of patients with concurrent depression and anxiety. Tianeptine 25 to 50 mg/day appears to have equivalent anxiolytic efficacy to fluoxetine 20 mg/day for 1.5 to 3 months, sertraline 50 mg/day for 1.5 months, amitriptyline 50 to 100 mg/day for 1 to 1.5 months, clomipramine 100 to 200 mg/day for 6 months and mianserin 30 to 80 mg/day for 1.5 or 6 months. Superior anxiolytic efficacy was attributed to tianeptine over maprotiline 75 mg/day for 2 months in a study of perimenopausal women with anxio-depressive symptoms.
Tianeptine 25 to 50 mg/day is effective as long term treatment to prevent relapse or recurrence in patients with depression. It also appears to have potential for use in specific subgroups. The efficacy of tianeptine 25 or 37.5 mg/day was equivalent to that of mianserin 30 mg/day and similar in some but not all parameters to that of fluoxetine 20 mg/day in elderly patients. Patients with chronic alcoholism often develop depression, especially on withdrawal of alcohol. Assessments of antidepressant and anxiolytic efficacy for tianeptine 37.5 mg/day were equivalent to those for amitriptyline 75 mg/day over 1 to 2 months in this patient population.
Improvements in quality-of-life scales with depressed tianeptine recipients were similar to those in patients receiving mianserin or fluoxetine.
The adverse effect profile of tianeptine appears to be similar in many respects to that of the SSRIs, in that cognitive, cardiovascular and bodyweight effects are minimal in comparison with the classical tricyclic antidepressant agents. In fact, in comparisons with placebo, the only symptom appearing significantly more often with tianeptine was headache. In clinical trials, the most common adverse effects seen in patients with depressive disorders receiving tianeptine were gastrointestinal (nausea, constipation, abdominal pain) or CNS (headache, dizziness, change in dreaming) disturbances, which decreased in frequency with continued treatment.
Effects such as dry mouth, hot flushes, somnolence, vertigo, gastrointestinal disturbances, increased bodyweight, increased heart rate and tremor occurred significantly more often in patients receiving tri- or tetracyclic antidepressant agents than in those receiving tianeptine. In studies comparing tianeptine with fluoxetine, paroxetine or sertraline, in contrast, the incidence of most adverse effects was similar; nausea, tremor and palpitations tended to occur more often in fluoxetine recipients, and the incidence of dry mouth tended to be higher in tianeptine recipients. Tianeptine has only rarely been associated with hepatoxicity.
The favourable tolerability profile of tianeptine has been confirmed in long term trials, and in elderly patients (including those with cardiovascular pathology before treatment initiation) and patients with alcoholism. The low incidence of anticholinergic and neurological effects associated with tianeptine is of particular importance in these subgroups, who have increased sensitivity to the adverse effects of psychotropic drugs.
Tianeptine has a wide therapeutic margin; overdosage has been associated with only minor transient adverse effects.
Dosage and Administration
The recommended dosage of tianeptine in patients with depression is 37.5 mg/day orally in 3 divided doses, with meals. The dosage should be reduced in elderly patients and patients with severe renal failure, but dosage reduction is not required in patients with chronic alcoholism or hepatic impairment or those undergoing haemodialysis.
The dosage of tianeptine should be reduced over 1 to 2 weeks when discontinuing treatment, although there is little evidence of psychological or physical dependence on the drug. As with other antidepressants, tianeptine is contraindicated in patients taking monoamine oxidase inhibitors.
KeywordsFluoxetine Clomipramine Mianserin Maprotiline Tianeptine
- 3.Labrid C, Mocaër E, Kamoun A. Neurochemical and pharmacological properties of tianeptine, a novel antidepressant. Br J Psychiatry 1992 Feb; 160 Suppl. 15: 56–60Google Scholar
- 4.Ansseau M. The paradox of tianeptine. Eur Psychiatry 1993; 8 Suppl. 2: 89s–93sGoogle Scholar
- 9.Kato G, Weitsch AF. Neurochemical profile of tianeptine, a new antidepressant drug. Clin Neuropharmacol 1988; 11 Suppl 2: S43–50Google Scholar
- 20.Bueno L, Fioramonti J, Rettori MC. Inhibition of stress-induced colonic motor alterations by tianeptine [abstract no. 782]. 9th World Congress of Psychiatry; 1993 Jun 6–12; Rio de Janeiro, 200Google Scholar
- 23.Curzon G, Datla KP. Effects of tianeptine on behavioural and neurochemical responses to immobilization stress. Eur Psychiatry 1993; 8Suppl. 2: 61s–6sGoogle Scholar
- 24.Curzon G, Kennett GA, Sarna GS, et al. The effects of tianeptine and other antidepressants on a rat model of depression. Br J Psychiatry 1992 Feb; 160 Suppl. 15: 51–5Google Scholar
- 26.Delbende C, Mocaër E, Rettori M, et al. Effect of the antidepressant tianeptine on the activity of the hypothalamo-pituitary-adrenal axis. Eur Psychiatry 1993; 8Suppl.2: 49s–54sGoogle Scholar
- 28.Fontanges R, Mimouni J, de Grieve X, et al. Effect of tianeptine on neuroendocrine, enzyme and behavioral responses to restraint stress in male rats. Eur Psychiatry 1993; 8Suppl. 2: 67s–73sGoogle Scholar
- 29.Guillaume V, Magnan E, Cataldi M, et al. Effect of tianeptine on the hypothalamic control of the corticotrophic response to stress. Eur Psychiatry 1993; 8Suppl.2: 55s–60sGoogle Scholar
- 32.McEwen BS, Angulo J, Gould E, et al. Antidepressant modulation of isolation and restraint stress effects on brain chemistry and morphology. Eur Psychiatry 1993; 8Suppl. 2: 41s–8sGoogle Scholar
- 43.Mocaër E, Rettori MC, Kamoun A. Pharmacological antidepressive effects and tianeptine-induced 5-HT uptake increase. Clin Neuropharmacol 1988; 11 Suppl. 2: S32–42Google Scholar
- 45.Lacroix P, Rocher N, Deslandes A. Antidepressant effects of tianeptine, of its two enantiomers and its predominant metabolite in the learned helplessness test in rats [abstract]. Eur Neuropsychopharmacol 1996 Sep; 6 Suppl. 4: 70Google Scholar
- 47.File SE, Andrews N, Zangrossi Jr H. Tianeptine counteracts the anxiogenic effects of benzodiazepine withdrawal, but not those of exposure to cat odour. Eur Psychiatry 1993; 8Suppl. 2: 75s–80sGoogle Scholar
- 55.Sommers DK, Van Wyk M, Snyman JR. Changes in the prolactin response to dexfenfluramine following tianeptine treatment. Med Sci Res 1997; 25(7): 477–8Google Scholar
- 56.Checkley S. Neuroendocrine mechanisms and the precipitation of depression by life events. Br J Psychiatry 1992; 160Suppl. 15: 7–17Google Scholar
- 58.Delbende C, Delarue C, Lefebvre H, et al. Glucocorticoids, transmitters and stress. Br J Psychiatry 1992 Feb; 160Suppl. 15: 24–34Google Scholar
- 60.Poirier MF, Galinowski A, Amado-Boccara I, et al. Effects of tianeptine on attention, memory and psychomotor performance using neuropsychological methods in young healthy volunteers. Eur Psychiatry 1993; 8Suppl. 2: 95s–102sGoogle Scholar
- 62.von Frenckell R, Ansseau M, Dulcire C, et al. Effects of tianeptine on vigilance and memory in young healthy volunteers. Psychiatr & Psychobio 1990; 5: 375–80Google Scholar
- 64.Mendlewicz J. Sleep EEG study of acute administration of tianeptine in ten young healthy volunteers. A double-blind placebo-controlled study. Servier. C-1574-214-BEL, volume 1/6; 1994 (Data on file)Google Scholar
- 66.Juvent M, Douchamps J, Delcourt E, et al. Lack of cardiovascular side effects of the new tricyclic antidepressant tianeptine. A double-blind, placebo-controlled study in young healthy volunteers. Clin Neuropharmacol 1990 Jan–Feb; 13: 48–57Google Scholar
- 67.Petrova E, Akopov G. Predictors of therapeutic efficacy of tianeptine in the treatment of panic disorders [abstract]. Neuropsychobiology 1997; 35(3): 167Google Scholar
- 71.Malka R, Lôo H, Ganry H, et al. Long-term administration of tianeptine in depressed patients after alcohol withdrawal. Br J Psychiatry 1992 Feb; 160Suppl. 15: 66–71Google Scholar
- 75.Bouver I, Farinotti R, Gelé P, et al. Metabolism of tianeptine after single and multiple dosing in man [abstract no. 31.02.35]. Psychopharmacology 1988; 96 Suppl.: 275Google Scholar
- 76.Riché C. The pharmacokinetics of tianeptine and its MC5 metabolite on repeated dosing in depressed adults. Servier. PMH 1574 01 021; Aug, 1991 (Data on file)Google Scholar
- 77.Salvadori C, Merdjan H, Brouard R, et al. Tianeptine and its main metabolite. Disposition in chronic renal failure and haemodialysis. Fundam Clin Pharmacol 1990; 4: 663–71Google Scholar
- 81.Jeanniot JP. A study of the pharmacokinetics of tianeptine and its metabolite MC5 in the elderly depressed patient after single and repeated administration of tianeptine sodium salt. Servier. P2.R.90.22.01574.HPK; Jun, 1991 (Data on file)Google Scholar
- 84.Ansseau M, Wauthy J, von Frenckell R, et al. Gradually increased doses of tianeptine: maximal tolerated dose and linearity of the pharmacokinetics [abstract]. An Psiquiatria 1992; 8Suppl. 1: 56Google Scholar
- 85.Ansseau M. Tolerance and pharmacokinetic study following single oral increasing doses of tianeptine sodium salt in healthy male volunteers. Servier. P2.R.92.10.01574.HPK; Jan, 1993 (Data on file)Google Scholar
- 87.Grasela TH, Fiedler-Kelly JB, Salvadori C, et al. Predictive performance of pre-marketing tianeptine pharmacokinetic parameters as applied to post-marketing data [abstract]. Clin Pharmacol Ther 1993 Feb; 53: 215Google Scholar
- 88.Les Laboratoires Servier. Tianeptine prescribing information. Neuilly-sur-Seine, France, 2000Google Scholar
- 89.Brion S, Audrain S, de Bodinat C. Episodes of severe depression in subjects over 70 years of age. Efficacy and acceptability of tianeptine and mianserine [in French]. Presse Med 1996; 25(9): 461–8Google Scholar
- 90.Faltus F, Novotny V. Comparison of efficacy of tianeptin and fluoxetin in treatment of depressive syndrome. Institut de Recherches Internationales Servier, 2000. (Data on file)Google Scholar
- 96.Paes de Sousa M, Figueira L, Ferreira L, et al. Efficacy and acceptability of tianeptine in the long-term treatment of major depression. Double blind trial: tianeptine vs clomipramine. Portugal: Servier Especialidades Farmacticas, Lda. 2000. (Data on file)Google Scholar
- 97.Svestka J, Synek O. Tianeptine versus dosulepine in the treatment of acute depressive disorders. A controlled study [poster]. 13th Congress of the European College of Neuropsychopharmacology; 2000 Sept 9–13; Munich, GermanyGoogle Scholar
- 99.Chaby L, Grinsztein A, Weitzman JJ, et al. Anxio-depressive disorders in menopausal and pre-menopausal women. Double blind study of tianeptine versus maprotiline [in French]. Presse Med 1993 Jul 3–10; 22: 1133–8Google Scholar
- 103.Alby JM, Ferreri M, Cabanne J, et al. Efficacy of tianeptine (Stablon™) for the treatment of major depression and dysthymia with somatic complaints. Acomparative study versus fluoxetine (Prozac™) [in French]. Ann Psychiatr 1993; 8(2): 136–44Google Scholar
- 104.Faltus F, Novotny V. Tianeptine for the treatment of major depressive episode: a double-blind study versus fluoxetine [poster]. 42nd Czech-Slovak Psychopharmacological Conference; 2000 Jan; Jesenik Spa, Czech RepublicGoogle Scholar
- 107.Waintraub L, Septien L, Azoulay P. Efficacy and safety of tianeptine in major depression: evidence from a 3-month controlled clinical trial versus paroxetine [abstract]. Eur Neuropsychopharmacol 2000 Apr; 10Suppl. 2: S51Google Scholar
- 108.Szádóczky E, Füredi J. Efficacy and acceptability of tianeptine and sertraline in acute treatment phase of depression. Neuropsychopharmacologia Hungarica 2000; II(4): 171–7Google Scholar
- 109.Lôo H, Ganry H, Dufour H, et al. Long-term use of tianeptine in 380 depressed patients. Br J Psychiatry 1992 Feb; 160Suppl. 15: 61–5Google Scholar
- 113.Raffaitin F Efficacy and acceptability of tianeptine in the elderly: a review of clinical trials. Eur Psychiatry 1993; 8Suppl.2: 117s–24sGoogle Scholar
- 114.Malauzat D, Danic C, Peyrouzet J-M, et al. The importance and need to prolong antidepressant treatment after the resolution of depression in elderly patients [in French]. Psychol Med 1990; 22(9): 903–22Google Scholar
- 124.Wittchen H-U, Knäuper B, Kessler R. Lifetime risk of depression. Br J Psychiatry 1994; 165Suppl. 26: 16–22Google Scholar
- 129.ASHP Commission on Therapeutics. ASHP therapeutic position statement on the recognition and treatment of depression in older adults. Am J Health System Pharm 1998 Dec 1; 55: 2514–8Google Scholar
- 131.Montgomery SA, Dufour H, Brion S, et al. The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry 1988; 153Suppl. 3: 69–75Google Scholar
- 140.Ballenger JC, Davidson JRT, Lecrubier Y, et al. Consensus statement on the primary care management of depression from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 1999; 60 Suppl. 7: 54–61Google Scholar